Atricure Stock Price, News & Analysis

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A prerecorded fireside chat is scheduled for November 22, 2021, accessible via the company's website. Additionally, management will hold investor meetings on December 1, 2021. AtriCure focuses on innovative technologies for Afib management, impacting over 33 million people globally, with notable products including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System.

AtriCure, a leader in atrial fibrillation treatments, reported strong Q3 2021 results with revenues of $70.5 million, a 28.7% increase year-over-year. U.S. revenue rose to $57.5 million due to stable cardiac procedures and high demand for Cryo Nerve Block and Hybrid AF therapy products. However, worldwide revenue fell by 1.3% from Q2 2021. Gross profit reached $52.2 million, with a gross margin of 74.1%. The company maintains its 2021 revenue guidance of $270-$275 million and adjusted EBITDA loss of approximately $10 million.

AtriCure, Inc. (NASDAQ: ATRC) announces participation in upcoming investor conferences, presenting at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. Eastern Time. A live audio webcast will be available on the company's website. Additionally, AtriCure will host investor meetings at the Canaccord Genuity Virtual MedTech Forum on November 18, 2021. AtriCure focuses on innovative surgical solutions for atrial fibrillation and left atrial appendage management, with devices like the FDA-approved Isolator® Synergy™ Ablation System.

AtriCure, a leader in atrial fibrillation (Afib) treatments, has announced the release of its third quarter 2021 financial results on November 3, 2021. A conference call will take place at 4:30 p.m. ET to discuss these results, which can be accessed via phone or through a live audio webcast. AtriCure's technologies, including the Isolator® Synergy™ Ablation System and AtriClip® products, are critical in treating over 33 million people affected by Afib globally. These innovations position AtriCure as a prominent player in the medical device market.

AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The presentation is set for Tuesday, September 14, 2021, at 11:45 a.m. Eastern Time. Attendees can access a live or archived audio webcast via the Investors section of AtriCure's website. AtriCure innovates treatments for Afib, impacting over 33 million people worldwide, and offers products like the Isolator® Synergy™ Ablation System and AtriClip® LAA management devices.

AtriCure, Inc. (Nasdaq: ATRC) reported a strong second quarter 2021, with revenue reaching $71.4 million, up 74.8% from the previous year. U.S. revenue saw a significant increase of 78.4% to $60.1 million, driven by recovery in cardiac procedures following COVID-19 disruptions. The company received FDA approval for the EPi-Sense® System, enhancing its treatment offerings. Adjusted EBITDA loss improved to $2.7 million. The 2021 revenue guidance has been updated to $270 to $275 million, reflecting 31% to 33% growth, although pandemic uncertainties remain a concern.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the Canaccord 41^st Annual Growth Conference. The company will present on August 11, 2021, at 8:00 a.m. Eastern Time. Interested participants can access the live and archived audio webcast on AtriCure’s website. AtriCure is known for its innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® for left atrial appendage management, addressing the needs of over 33 million Afib sufferers globally.

AtriCure, Inc. (Nasdaq: ATRC) has announced the release date for its second quarter 2021 financial results, set for August 4, 2021. A conference call will take place at 4:30 p.m. ET on the same day, allowing stakeholders to discuss the results. AtriCure specializes in innovative treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, with its technologies widely used by healthcare professionals. The company aims to improve outcomes for the over 33 million people affected by Afib globally.

AtriCure, Inc. (Nasdaq: ATRC) announced the election of Deborah H. Telman and Maggie Yuen to its Board of Directors. Ms. Telman brings over 20 years of executive experience, notably at Organon and Sorrento Therapeutics, with expertise in legal affairs and compliance. Ms. Yuen, currently CFO at Penumbra, has extensive experience in finance and operations within the medical device sector. Both executives aim to advance AtriCure's mission in treating atrial fibrillation and enhancing growth opportunities in the healthcare space.